Ken Griffin Dare Bioscience, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dare Bioscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 161,277 shares of DARE stock, worth $66,123. This represents 0.0% of its overall portfolio holdings.

Number of Shares

161,277

Holding current value

$66,123

% of portfolio

0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$0.31 - $0.57 $49,995 - $91,927	161,277 New	161,277 $79,000
Q3 2023 Nov 14, 2023	BUY	$0.46 - $0.91 $37,943 - $75,061	82,485 Added 165.3%	132,386 $60,000
Q2 2023 Aug 14, 2023	SELL	$0.91 - $1.05 $177,213 - $204,477	-194,740 Reduced 79.6%	49,901 $45,000
Q1 2023 May 15, 2023	BUY	$0.87 - $1.36 $212,837 - $332,711	244,641 New	244,641 $254,000
Q2 2022 Aug 15, 2022	SELL	$0.94 - $1.76 $39,835 - $74,585	-42,378 Closed	0 $0

Q1 2022 May 16, 2022	SELL	$1.42 - $2.09 $34,413 - $50,651	-24,235 Reduced 36.38%	42,378 $63,000
Q3 2021 Nov 15, 2021	BUY	$1.42 - $2.0 $94,590 - $133,226	66,613 New	66,613 $111,000
Q1 2021 May 17, 2021	SELL	$1.31 - $3.0 $84,594 - $193,728	-64,576 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$0.96 - $1.51 $61,992 - $97,509	64,576 New	64,576 $87,000
Q2 2019 Aug 14, 2019	SELL	$0.79 - $1.66 $12,841 - $26,983	-16,255 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$0.73 - $2.1 $65,760 - $189,174	-90,083 Reduced 84.71%	16,255 $0
Q3 2018 Nov 13, 2018	BUY	$0.92 - $1.43 $65,752 - $102,202	71,470 Added 204.97%	106,338 $0
Q2 2018 Aug 10, 2018	BUY	$0.76 - $1.48 $26,499 - $51,604	34,868 New	34,868 $0
Q1 2018 May 11, 2018	SELL	$0.83 - $2.79 $9,362 - $31,471	-11,280 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$2.16 - $3.35 $24,364 - $37,788	11,280	11,280 $24,000

Others Institutions Holding DARE

# of Institutions

Shares Held

6.86M

Call Options Held

Put Options Held

View Full List

About Dare Bioscience, Inc.

Ticker DARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,820,896
Market Cap $34.8M
Description
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in the identifying, developing, and marketing products for women's health in the United States. It develops therapies in the areas of contraception, fertility, and sexual and vaginal health. The company's product includes XACIATO, a single-dose vaginal gel prescription pr...

More about DARE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account